La vendita allo scoperto per CohBar Inc dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di CohBar Inc. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

CohBar Inc (OTC:CWBR) Azioni, Report sulle vendite allo scoperto

CohBar

CohBar Inc

HC Wainwright &amp; Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) with a Buy and maintains $7 price target.

News

Price Target

Reiteration

Analyst Ratings

OKYO

HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target

Findell Capital Management LLC (collectively with its affiliates, "Findell" or "we"), which beneficially owns approximately 9.5% of the outstanding common stock of Oportun Financial Corporation (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>), today issued a public letter to the Company's stockholders and launched a campaign website at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4419145-1&amp;h=2449506232&amp;u=http%3A%2F%2Fwww.opportunityatoportun.com%2F&amp;a=www.OpportunityAtOportun.com">www.OpportunityAtOportun.com</a> that contains important information about Findell's campaign. A copy of the letter is below.
Fellow Oportun Stockholders:
We are the largest stockholder of Oportun Financial Corporation ("Oportun" or the "Company"), with an approximately 9.5% equity stake in the Company. Over the last two years, we have repeatedly urged Oportun's Board of Directors (the "Board") to act as an honest fiduciary rather than as a captive enabler of CEO Raul Vazquez. Our efforts resulted in the addition to the Board in 2024 of independent directors Scott Parker and Richard Tambor, who each possess valuable experience in direct lending and whose appointments resulted in significant improvements in credit and cost reductions.
However, we believe Oportun today remains hamstrung by legacy directors and executives who continue to delay further operational and governance enhancements that would create meaningful value for stockholders. We have concluded that additional change to the composition of the Board is needed to ensure the Board's independence from management and to realize the full potential of Oportun.
To that end, we have nominated Warren Wilcox, an independent and highly qualified director candidate, for election to the Board at the 2025 Annual Meeting of Stockholders (the "Annual Meeting"). Mr. Wilcox is a seasoned lender whose election will end the legacy directors' majority control of the Board and enable the Board to provide effective long-term oversight of the business.
We will soon be mailing you a proxy statement and a&nbsp;WHITE&nbsp;universal proxy card where you will have an opportunity to vote on the future of the Company. In the meantime, you may find additional information on our newly launched campaign website: <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4419145-1&amp;h=2449506232&amp;u=http%3A%2F%2Fwww.opportunityatoportun.com%2F&amp;a=www.OpportunityAtOportun.com">www.OpportunityAtOportun.com</a>.
The Legacy Board Has Failed to Turn Around Oportun's Underperformance &amp; Effectively Oversee CEO Vazquez
In our view, Mr. Vazquez has destroyed a great lending business by ballooning Oportun's cost structure and net charge offs while attempting to turn the Company into a fintech conglomerate and a personal empire. We believe Mr. Vazquez's mistakes should have been arrested at the Board level – something the Board has evidently been incapable of or unwilling to do. In fact, the Board has apparently only encouraged Mr. Vazquez, most recently by appointing him Chief Financial Officer and principal accounting officer in addition to his role as CEO, despite his lack of accounting experience. This ineffective oversight is unsurprising in light of the facts that not a single legacy director has lending experience, and that many legacy directors have close personal and professional ties to Mr. Vazquez.
Our calls for Oportun to reverse Mr. Vazquez's empire-building efforts and refocus on its core lending business eventually forced a course correction, which was further aided by the addition of Messrs. Parker and Tambor in 2024. However, the changes have come slowly – and stockholders have had to suffer a 40% dilution1 since our engagement began in order to cover the Company's strategic blunders.
While the Company has made slow progress, Oportun is still substantially underperforming as evidenced by its operating results and by the subpar performance targets that have been set by the Board, which suggest that there is no sense of urgency in fixing the business. We believe that Oportun will not move forward so long as it maintains a staggered 10-person Board that is controlled by six long-tenured legacy directors who comprise the entirety of its committee and Board leadership.
The Company's operational and strategic performance under the supervision of the legacy directors clearly demonstrates the need for change:
<ul>
<li>While competitors like OneMain Holdings, Inc. ("OMF") kept their operating expenses ("opex") per loan and corporate head count flat from 2019 to 2023, Oportun grew its aggressively by 109% and 70%.2</li>
<li>Unnecessary acquisitions caused the Company to deviate from its core lending mission and generated substantial losses – for instance, the Company wasted $211 million on the value-destructive acquisition of Hello Digit, Inc. in 2021, or 12x its book value.3</li>
</ul>
These problems arose, we believe, from serious flaws in the Company's governance structure, which seems designed to negate accountability and facilitate management's value-destructive behavior:
<ul>
<li>Despite its small market capitalization (&lt;$200 million), Oportun is overseen by a bloated 10-person staggered Board with only four directors who appear independent from management.</li>
<li>Many of the legacy directors have worked with each other and with Mr. Vazquez in prior professional roles, forcing us to question the degree of independent oversight actually being exercised.4</li>
<li>Not one of the six legacy Board members has lending experience.</li>
<li>When we urged the Board to shrink from 10 directors to eight, the Board refused.</li>
</ul>
Since the appointment of Messrs. Parker and Tambor in 2024 as part of our cooperation agreement with the Company, Oportun's total return has meaningfully improved, demonstrating the importance of proper Board oversight:5
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Metric</td>
<td colspan="1" rowspan="1">Start</td>
<td colspan="1" rowspan="1">End</td>
<td colspan="1" rowspan="1">Total Return</td>
<td colspan="1" rowspan="1">Russell 2000</td>
<td colspan="1" rowspan="1">OMF</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Findell Directors Put on Board</td>
<td colspan="1" rowspan="1">04-22-2024</td>
<td colspan="1" rowspan="1">04-21-2025</td>
<td colspan="1" rowspan="1">96.44&nbsp;%</td>
<td colspan="1" rowspan="1">-5.89&nbsp;%</td>
<td colspan="1" rowspan="1">-3.95&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2 Years</td>
<td colspan="1" rowspan="1">04-21-2023</td>
<td colspan="1" rowspan="1">04-21-2025</td>
<td colspan="1" rowspan="1">17.87&nbsp;%</td>
<td colspan="1" rowspan="1">4.93&nbsp;%</td>
<td colspan="1" rowspan="1">35.55&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">3 Years</td>
<td colspan="1" rowspan="1">04-21-2022</td>
<td colspan="1" rowspan="1">04-21-2025</td>
<td colspan="1" rowspan="1">-65.20&nbsp;%</td>
<td colspan="1" rowspan="1">-4.27&nbsp;%</td>
<td colspan="1" rowspan="1">17.06&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">5 Years</td>
<td colspan="1" rowspan="1">04-21-2020</td>
<td colspan="1" rowspan="1">04-21-2025</td>
<td colspan="1" rowspan="1">-24.96&nbsp;%</td>
<td colspan="1" rowspan="1">64.37&nbsp;%</td>
<td colspan="1" rowspan="1">320.11&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">IPO</td>
<td colspan="1" rowspan="1">09-26-2019</td>
<td colspan="1" rowspan="1">04-21-2025</td>
<td colspan="1" rowspan="1">-72.67&nbsp;%</td>
<td colspan="1" rowspan="1">27.95&nbsp;%</td>
<td colspan="1" rowspan="1">122.34&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
It's important to highlight that we endeavored to avoid a proxy fight this year by seeking to collaborate with Oportun on a plan that would place directors with lending experience in Board leadership positions. Unsurprisingly, the legacy directors refused our offers, further demonstrating that they are more focused on retaining their positions and keeping the current management team in place instead of driving stockholder returns.
In March of this year, we offered two experienced and independent director candidates to the Company whose addition to the Board would, we believed, provide it with significant lending expertise and promote good governance. Now that it has become apparent to us that no collaborative solution is possible, we have withdrawn one of our recommended candidates and are focusing our efforts on electing industry veteran Mr. Wilcox at the Annual Meeting to end the legacy directors' control over the Board.
This Year's Election Contest Represents an Opportunity to Establish an Independent Board Led by Independent Lending Industry Veterans
With the election of Mr. Wilcox at this year's Annual Meeting, stockholders can once and for all ensure that the entrenched legacy members no longer control the Board. Mr. Wilcox's addition to the Board will ensure that the Board is led by independent directors with lending industry experience and a level of objectivity that will enable them to effectively oversee management.
We also urge Oportun to take the following actions, which we believe will result in sustainable value creation for stockholders:
<ul>
<li>Further reduce costs so that the Company's opex ratio, which currently stands at 15%, targets 10% and is more in line with best-in-class operator OMF at less than 7%.</li>
<li>Remove the self-imposed interest rate cap of 36% so that Oportun can better serve its customer base.</li>
<li>De-stagger the Board and ensure it is fully independent with no professional or personal ties to management.</li>
<li>Appoint current directors with lending experience (Mr. Parker, Mr. Tambor and Carlos Minetti) to Board leadership roles.</li>
</ul>
We believe that much better days lie ahead for Oportun once stockholders wrest control of the Company from its irresponsible legacy directors and imperial CEO. In the coming weeks, we look forward to sharing additional information regarding the qualifications of Mr. Wilcox and our plan to unlock Oportun's full potential.
Sincerely,
Brian Finn CIO Findell Capital

Management

OPRT

Findell Capital Pushes for Change at Oportun, Nominates Veteran Director for Board

Rosenblatt analyst Blair Abernethy maintains Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) with a Buy and lowers the price target from $62 to $53.

Rosenblatt Maintains Buy on Bentley Systems, Lowers Price Target to $53

Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors
Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital Partners, Earth Foundry, Rsquared VC, In-Q-Tel (IQT), and other undisclosed investors
Varun Mehta, previously founder of Nimble Storage, to serve as CEO of Atlas Data Storage
Twist remains focused on serving customers across the life sciences spectrum and expanding revenue and gross margin while driving toward adjusted EBITDA breakeven, now expected by the end of fiscal 2026
Twist to retain minority ownership in Atlas Data Storage
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.twistbioscience.com%2F&amp;esheet=54248406&amp;newsitemid=20250505213784&amp;lan=en-US&amp;anchor=Twist+Bioscience+Corporation&amp;index=1&amp;md5=ab4c0cc27c1052499c1fbf60a4b0e1e7">Twist Bioscience Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that the company has spun out its DNA data storage technology application as an independent company, named Atlas Data Storage ("Atlas").
Under the terms of the contribution and license agreements, Twist assigned and licensed its DNA data storage technology to Atlas in exchange for Twist receiving a minority ownership interest upon close, an upfront cash payment and a secured promissory note. Twist retains an ownership stake in Atlas and may participate in the upside of DNA data storage through future technology and commercial milestone payments, and a revenue share through royalties on future sales of Atlas' products and services. In addition, Twist will benefit from technology advancements made by Atlas where it applies to Twist's product groups.
 &nbsp;

TWST

Twist Bioscience Spins Out DNA Data Storage Technology Application As Independent Company, Named Atlas Data Storage

Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(1.33) by 48.87 percent. This is a 32 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $121.46 million which beat the analyst consensus estimate of $119.87 million by 1.33 percent. This is a 61.95 percent increase over sales of $75.00 million the same period last year.

Earnings

Earnings Beats

AXSM

Axsome Therapeutics Q1 Adj. EPS $(0.68) Beats $(1.33) Estimate, Sales $121.46M Beat $119.87M Estimate

BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) reported quarterly sales of $145.53 million which beat the analyst consensus estimate of $126.87 million by 14.71 percent. This is a 56.89 percent increase over sales of $92.76 million the same period last year.

BCRX

BioCryst Pharma Q1 Sales $145.53M Beat $126.87M Estimate

Telsey Advisory Group analyst Sarang Vora maintains Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) with a Outperform and maintains $52 price target.

VITL

Telsey Advisory Group Maintains Outperform on Vital Farms, Maintains $52 Price Target

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is looking for Q2 Adj EPS of $0.41-$0.44 vs $0.43 analyst estimate. sees sales of $19.700 million-$19.900 million vs $19.81 million analyst estimate.

Guidance

IRMD

iRadimed Sees Q2 Adj EPS $0.41-$0.44 vs $0.43 Est; Sees Sales $19.700M-$19.900M vs $19.81M Est

Rafael Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) today announced revised subscription rights in connection with its previously announced rights offering.
Holders of record as of May 9, 2025 (the "Record Date") will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025.
Under the proposed rights offering, Rafael Holdings intends to distribute one (1) non-transferable subscription right for each share of Class B Common Stock or Class A Common Stock or share of Class B Common Stock purchasable on exercise of Public Warrants, in each case, held as of the Record Date. Each subscription right will entitle the Holder to purchase 0.603 of a share of Class B Common Stock at a subscription price of $1.28 per share. Subscription rights may only be exercised in whole numbers, and fractional shares will not be issued. The number of shares that may be purchased by each holder of subscription rights will be rounded down to the nearest whole number.
 &nbsp;

Rafael Holdings Revises Subscription Rights Following Prior $25M Rights Offering To Support Development And Potential Launch Of Trappsol Cyclo

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) affirms FY2025 GAAP EPS guidance from $1.55-$1.65 to $1.55-$1.65 vs $1.64 analyst estimate..

iRadimed Affirms FY2025 GAAP EPS Guidance of $1.55-$1.65 vs $1.64 Est

HC Wainwright &amp; Co. analyst Yi Chen reiterates Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) with a Buy and maintains $50 price target.

TRML

HC Wainwright & Co. Reiterates Buy on Tourmaline Bio, Maintains $50 Price Target

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is looking for Q2 GAAP EPS of $0.37-$0.40 vs $0.41 analyst estimate..

iRadimed Sees Q2 GAAP EPS $0.37-$0.40 vs $0.41 Est

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) affirms FY2025 Adj EPS guidance from $1.71-$1.81 to $1.71-$1.81 vs $1.75 analyst estimate. Affirms FY2025 sales outlook from $78.00 million-$82.00 million to $78.00 million-$82.00 million vs $79.41 million estimate.

iRadimed Affirms FY2025 Adj EPS Guidance of $1.71-$1.81 vs $1.75 Est; Affirms FY2025 Sales Guidance of $78.00M-$82.00M vs $79.41M Est

Telsey Advisory Group analyst Dana Telsey maintains FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) with a Market Perform and lowers the price target from $7 to $5.

FIGS

Telsey Advisory Group Maintains Market Perform on FIGS, Lowers Price Target to $5

<ul>
<li>MaGic trial exceeded enrollment target of 60 patients</li>
<li>Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26</li>
<li>Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential&nbsp;best-in-class, potent classical pathway inhibitor intended as a self-administered&nbsp;autoinjector dosed once every two weeks</li>
</ul>

DNTH

Dianthus Completes Enrollment In Phase 2 MaGic Trial Of DNTH103 For gMG, Top-Line Results Expected September

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

Needham analyst Laura Martin maintains FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) with a Buy and lowers the price target from $3.35 to $3.

FUBO

Needham Maintains Buy on FuboTV, Lowers Price Target to $3

Sunoco LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) ("Sunoco" or the "Partnership") and Parkland Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PKI#TSX">PKI</a>) ("Parkland") announced today that the parties have entered into a definitive agreement whereby Sunoco will acquire all outstanding shares of Parkland in a cash and equity transaction valued at approximately $9.1 billion, including assumed debt. &nbsp;
&nbsp;
As part of the transaction, Sunoco intends to form a new publicly-traded Delaware limited liability company named SUNCorp, LLC ("SUNCorp"). SUNCorp will hold limited partnership units of Sunoco that are economically equivalent to Sunoco's publicly-traded common units on the basis of one Sunoco common unit for each outstanding SUNCorp unit.&nbsp;This new publicly-traded entity will be treated as a corporation for tax purposes. For a period of two years following closing of the transaction, Sunoco will ensure that SUNCorp unitholders will receive the same dividend equivalent as the distribution to Sunoco unitholders.
Transaction Details
Under the terms of the agreement, Parkland shareholders will receive 0.295 SUNCorp units and C$19.80 for each Parkland share, implying a 25% premium based on the 7-day VWAP's of both Parkland and Sunoco as of May 2, 2025. Parkland shareholders can elect, in the alternative, to receive C$44.00 per Parkland share in cash or 0.536 SUNCorp units for each Parkland share, subject to proration to ensure that the aggregate consideration payable in connection with the transaction does not exceed C$19.80 in cash per Parkland share outstanding as of immediately before close and 0.295 SUNCorp units per Parkland share outstanding as of immediately before close.
Sunoco has secured a $2.65 billion 364-day bridge term loan for the proposed cash consideration.
The transaction has been unanimously approved by the board of directors of both companies and is expected to close in the second half of 2025 upon the satisfaction of closing conditions, including approval by Parkland's shareholders and customary regulatory and stock exchange listing approvals.

TSX:PKI

Sunoco to Acquire Parkland Corporation in $9.1B Cash and Equity Deal

RIME

Algorhythm's Subsidiary Announced The Acquisition Of 9,999 Of The 10,000 Issued And Outstanding Equity Shares Of Semicab India In Exchange Of A $1.75M Promissory Note And 119,742 Shares Of Its Common Stock

Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 35.71 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $10.70 million which missed the analyst consensus estimate of $16.83 million by 36.44 percent. This is a 27.59 percent decrease over sales of $14.77 million the same period last year.

Comments

CohBar Inc

Vendite allo scoperto

CohBar Inc (OTC:CWBR) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO